Italia markets close in 2 hours 34 minutes

OPKO Health, Inc. (0KCS.L)

LSE - LSE Prezzo differito. Valuta in USD.
Aggiungi a portafoglio
3,7200+0,6500 (+21,17%)
Al 07:09PM GMT. Mercato aperto.
Schermo intero
Chiusura precedente3,0700
Denaro0,0000 x N/D
Lettera0,0000 x N/D
Min-Max giorno2,9700 - 3,1700
Intervallo di 52 settimane2,9700 - 3,1700
Media VolumeN/D
Beta (5 anni mensile)1,73
Rapporto PE (ttm)31,53
EPS (ttm)0,1180
Prossima data utili16 feb 2022 - 21 feb 2022
Rendimento e dividendo (forward)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Japan’s MHLW Approves Pfizer and OPKO’s NGENLA® (Somatrogon), a New Long-Acting Treatment for Pediatric Growth Hormone Deficiency

    NGENLA® offers a new once-weekly treatment option for children living with growth hormone deficiencyTOKYO and MIAMI, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Pfizer Japan Inc. and OPKO Health, Inc. (NASDAQ: OPK) announced today that the next generation long-acting growth hormone injection, NGENLA® (somatrogon) Inj. 24 mg Pens and 60 mg Pens, has been approved by the Ministry of Health, Labour and Welfare (MHLW) in Japan. NGENLA® is a once-weekly long-acting recombinant human growth hormone, for the ind

  • GlobeNewswire

    Sema4 to Acquire GeneDx, Strengthening its Market-Leading AI-Driven Genomic and Clinical Data Platform

    Business combination projected to deliver $350 million in pro forma 2022 revenue $200 million private placement from leading growth and life sciences investors, including Pfizer, will fortify transaction and Sema4 balance sheet Katherine Stueland, CEO of GeneDx and former CCO of Invitae, to join Sema4 as Co-CEO, alongside Eric Schadt, PhD, and become a member of Sema4’s Board of Directors Director Jason Ryan, former CFO of Foundation Medicine, to assume role of Executive Chair of Sema4’s Board o

  • GlobeNewswire

    OPKO Health Announces Topline Results from Phase 2 Trial Evaluating RAYALDEE to Treat Symptomatic COVID-19 Outpatients

    Preliminary data indicate that improving vitamin D status with oral RAYALDEE results in earlier resolution of respiratory symptoms associated with COVID-19MIAMI, Dec. 23, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) announces preliminary topline results from its Phase 2 trial with RAYALDEE® to treat mild-to-moderate COVID-19. This study builds on increasing medical evidence that vitamin D repletion therapy can mitigate the severity of upper respiratory tract infections and accelerate